Bio/Pharma News

Sep 12, 2017
By Pharmaceutical Technology Editors
Alexion’s restructuring will reduce its global workforce by 20%, including closing a manufacturing facility in Rhode Island.
Sep 12, 2017
By Pharmaceutical Technology Editors
The meeting, to be held jointly with the European Centre for Disease Prevention and Control, is part of the agency’s effort to raise awareness about the threat of antimicrobial resistance.
Sep 11, 2017
By Pharmaceutical Technology Editors
J&J’s Janssen ends a 2015 collaboration with Achillion Pharmaceuticals with a strategic decision to discontinue further development of a hepatitis C therapy in favor of pursuing hepatitis B therapeutics.
Sep 08, 2017
By Pharmaceutical Technology Editors
The pharma major anticipates an annualized cost savings of roughly $500 million starting in 2018 based on a significant reduction in its global workforce.
Sep 07, 2017
By Pharmaceutical Technology Editors
Roche’s subsidiary, Genentech, issued the voluntary recall of the anti-stroke drug because of compromised vials containing sterile water that were packaged with the drug.
Sep 07, 2017
By Pharmaceutical Technology Editors
With this acquisition, Merck gains a lead anti-tumor drug candidate and a proprietary technology that can potentially induce immediate and long-term anti-tumor immunity.
Sep 07, 2017
By Pharmaceutical Technology Editors
Merck KGaA completes the divestment of its biosimilars business as part of its strategy to focus on developing a pipeline of innovator drugs.
Sep 07, 2017
By Pharmaceutical Technology Editors
As Merck KGaA continues its strategic shift into a science and technology company, it is considering options for its Consumer Health business, including a potential sale.
Sep 06, 2017
By Pharmaceutical Technology Editors
Pfizer’s Mylotarg, an anti-body drug conjugate once voluntarily withdrawn, returns to the market under a new dosing regimen for treating leukemia.
Sep 05, 2017
By Pharmaceutical Technology Editors
Novartis has appointed Dr. Vasant Narasimhan as CEO.
native1_300x100
lorem ipsum